PPAR Research
Volume 2018 (2018), Article ID 4292509, 8 pages
https://doi.org/10.1155/2018/4292509

Research Article

Treatment with Lobeglitazone Attenuates Hepatic Steatosis in Diet-Induced Obese Mice

Sorim Choung,¹ Kyong Hye Joung,² Bo Ram You,² Sang Ki Park,² Hyun Jin Kim,² and Bon Jeong Ku1,2

¹Department of Medical Science, College of Medicine, Chungnam National University, Daejeon 35015, Republic of Korea
²Department of Internal Medicine, College of Medicine, Chungnam National University, Daejeon 35015, Republic of Korea

Correspondence should be addressed to Bon Jeong Ku; bonjeong@cnu.ac.kr

Received 10 October 2017; Revised 22 January 2018; Accepted 20 May 2018; Published 13 June 2018

Academic Editor: Ruth Roberts

Copyright © 2018 Sorim Choung et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract.

Nonalcoholic fatty liver disease (NAFLD) is strongly associated with insulin resistance. The peroxisome proliferator-activated receptor (PPAR) activators, thiazolidinediones, (TZDs), are insulin sensitizers used as a treatment for NAFLD. However, TZDs are a controversial treatment for NAFLD because of conflicting results regarding hepatic steatosis and fibrosis. To evaluate a possible effective drug for treatment of NAFLD, we investigated the effects of a newly developed TZD, lobeglitazone, with an emphasis on hepatic lipid metabolism. Lobeglitazone treatment for 4 weeks in high fat diet- (HFD-) induced obese mice (HL group) improved insulin resistance and glucose intolerance compared to HFD-induced obese mice (HU group). The gene levels related to hepatic gluconeogenesis also decreased after treatment by lobeglitazone. The livers of mice in the HL group showed histologically reduced lipid accumulation, with lowered total plasma cholesterol and triglyceride levels. In addition, the HL group significantly decreased the hepatic expression of genes associated with lipid synthesis, cholesterol biosynthesis, and lipid droplet development and increased the hepatic expression of genes associated with fatty acid β-oxidation, thus suggesting that lobeglitazone decreased hepatic steatosis and reversed hepatic lipid dysregulation. Livers with steatohepatitis contained increased levels of PPARγ and phosphorylated PPARγ at serine 273, leading to downregulation of expression of genes associated with insulin sensitivity. Notably, the treatment of lobeglitazone increased the protein levels of PPARα and diminished levels of PPARγ phosphorylated at serine 273, which were increased by a HFD, suggesting that induction of PPARα and posttranslational modification of PPARγ in livers by lobeglitazone might be an underlying mechanism of the improvement seen in NAFLD. Taken together, our data showed that lobeglitazone might be an effective treatment for NAFLD.

1. Introduction

Nonalcoholic fatty liver disease (NAFLD) is becoming a serious clinical problem because of an increased number of obese and overweight patients [1]. Although the number of NAFLD patients is growing rapidly, there is no optimal therapy for this disorder [2]. NAFLD is related to obesity, diabetes, hyperlipidemia, and a high fat diet (HFD), which are conditions linked with insulin resistance [3]. Insulin resistance causes an uncontrolled release of free fatty acids from adipose tissue and multiple alterations of fat metabolism in the liver [4]. NAFLD could therefore be induced by an imbalance caused by exacerbated hepatic lipid accumulation and ameliorated lipid build-up.

The peroxisome proliferator-activated receptor (PPAR) is a member of the nuclear receptor superfamily of ligand-inducible transcription factors, comprising PPARα, PPARβ/δ, and PPARγ. PPARγ, which is a master regulator of gene expression in metabolic, inflammatory, and other pathways [5], improves insulin sensitivity through upregulation of glucose/lipid uptake and storage, mainly in adipose tissue [6]. The thiazolidinediones (TZDs) are synthetic activators of PPARγ that induce insulin sensitization as a treatment for type 2 diabetes mellitus (T2DM). Rosiglitazone and pioglitazone, which are members of the TZD family, have been studied as the drug for the treatment of NAFLD. Many studies have suggested that rosiglitazone and pioglitazone indirectly improve NAFLD through enhancing fatty acid uptake and adiponectin secretion of the adipose tissue, which is the main organ that express the PPARγ [7, 8]. It is still unclear whether the hepatic PPARγ activation by TZD is main mechanism to directly improve hepatic steatosis.

Lobeglitazone, a dual activator of PPARα and PPARγ, has recently been approved in The Republic of Korea and is being used to treat T2DM following the completion of clinical trials [9]. Animal studies showed that lobeglitazone inhibited renal fibrosis through regulation of the TGF-β/Smad3 pathway [10] and ameliorated inflammation of white adipocytes [11]. T2DM patients treated with lobeglitazone showed improvements in hepatic steatosis, hyperglycemia, and insulin resistance [2, 12]. One study reported that lobeglitazone was mainly localized to the liver [13], suggesting that it could have potent effects for improving insulin sensitivity and lipid metabolism in the liver compared to other TZDs. However, there is no clear evidence that lobeglitazone improved NAFLD through direct effects on the liver.

In the present study, we therefore characterized the effects of lobeglitazone in an animal model of obesity-associated hepatic steatohepatitis, focusing on lipid metabolism in the liver.

2. Materials and Methods

2.1. Animals

Male C57BL/6J mice were purchased from Harlan (Indianapolis, IN, USA). A HFD (D12492) comprising 60% fat was purchased from Research Diets (New Brunswick, NJ, USA). The animals were maintained in a controlled environment (12 hours of light/12 hours of dark) with a humidity of 50%–60% and an ambient temperature of 22 ± 2°C. The 6-week-old male mice were fed a normal chow diet (NCD) or HFD for 8 consecutive weeks and then divided randomly into three groups: a group of mice fed the NCD without treatment (NU group), a group of mice fed the HFD without untreatment (HU group), and a group of mice fed an HFD with lobeglitazone treatment (Duvie, 5 mg/kg/day; oral gavage) for the final 4 weeks (HL group). All experimental procedures were conducted in accordance with the guidelines of the Institutional Animal Care and Use Committee, Chungnam National University School of Medicine, Daejeon, Republic of Korea.

2.2. Histological Analysis

In all groups, tissue samples were obtained from 18-week-old mice. Samples for light microscopy were fixed in 4% paraformaldehyde for 1 hour. Paraffin embedding, sectioning, hematoxylin and eosin (H&E), and Oil Red O staining were performed according to standard protocols. The Oil Red O stained sections were also quantified by digital image analysis (DIA) using image-dedicated software (ImageJ) [14].

2.3. Serum Biochemical Measurements

Blood was collected from the heart under general anesthesia. The samples were centrifuged at 5,000 rpm for 5 minutes and the supernatants collected. Serum insulin was measured using an ELISA kit (Alpco Diagnostics, Salem, NH, USA). Biochemical analyses, including determination of free fatty acids and total cholesterol, were performed using a Hitachi 7180 auto analyzer (Tokyo, Japan) and reagents (Wako Pure Chemical Industries, Osaka, Japan).

2.4. Intraperitoneal Glucose Tolerance Test (IPGTT) and Insulin Tolerance Test (ITT)

For the IPGTT, mice were fasted for 16 hours, and then 2 g/kg glucose was injected into the intraperitoneal cavity. Blood glucose levels were measured at 0, 15, 30, 60, 90, and 120 minutes using a glucometer (Accu-Chek; Roche, Basel, Switzerland). The ITT was performed by measuring blood glucose after 6 hours of fasting, followed by intraperitoneal injection of 0.75 U/kg insulin (Humalog; Eli Lilly, Indianapolis, IN, USA).

2.5. Western Blot Analysis

The livers from mice were lysed in RIPA buffer (30 mM Tris, pH 7.5, 150 mM sodium chloride, 1 mM phenylmethylsulfonyl fluoride, 1 mM sodium orthovanadate, 1% Nonidet P-40, 10% glycerol, containing phosphatase, and protease inhibitors). Western blot analyses were performed with 30–50 μg protein from the tissue homogenate using commercially available antibodies to the following: antisterol responsive elementary binding protein (Srebp) 1 and Srebp2 (BD Biosciences, San Jose, CA, USA), fatty acid synthase (Fasn), PPARα and PPARγ (Cell Signaling Technology, Danvers, MA, USA), acid binding cassette A1 (ABCA1) (Millipore, Hayward, CA, USA), and phosphoPPARγ (S273) (Bioss, Centennial, CO, USA). Secondary antibodies (goat anti-mouse and goat anti-rabbit) were obtained from Cell Signaling Technology.

2.6. Isolation of RNA and Analysis by Real-Time PCR

Total RNA was isolated using TRIzol reagent (Thermo Fisher Scientific, Scotts Valley, CA, USA), and cDNA was prepared from total RNA using M-MLV reverse transcription and oligo-dT primers (Invitrogen, Carlsbad, CA, USA). The resultant cDNA was amplified using Rotor-Gene™ 6000 real-time rotary analysis software (ver. 1.7; Corbett Life Science, Mortlake, Australia). Real-time PCR was performed in triplicate with individual time-matched, vehicle-treated, or control mice using QuantiTect™ SYBR® Green PCR Master Mix (Qiagen, San Diego, CA, USA). All quantitative calculations were performed using the ΔΔCT method.

2.7. Statistical Analysis

Statistical analyses were performed using Graph Prism 5 (GraphPad, La Jolla, CA, USA). Data are reported as means ± SEM. All data from animal studies were analyzed by two-way repeated-measures analysis of variance followed by Bonferroni correction for multiple comparisons, one-way analysis of variance followed by Tukey’s post hoc test, or two-tailed Student’s t-test. A p-value < 0.05 was considered statistically significant.

3. Results

3.1. Lobeglitazone Treatment Improves Insulin Resistance in HFD-Induced Obese Mice

After feeding of a HFD for 12 weeks, C57BL/6J mice showed a significant increase in body weight compared with mice fed a NCD (data not shown). We confirmed the effects of a HFD through which the HU group showed the glucose intolerance on the IPGTT (Figure 1(a)) and insulin resistance on the ITT (Figure 1(b)) compared with the NU group. The HL group significantly improved glucose tolerance and insulin sensitivity compared with the HU group (Figures 1(a) and 1(b)). Fasting plasma glucose and insulin levels were also markedly lower in the HL group compared with the HU group (Figures 1(c) and 1(d)), resulting in an improved homeostasis model assessment of insulin resistance (HOMA-IR) index in the HL group (Figure 1(e)). In addition, glucose-regulating enzymes in the liver, such as PEPCK and G6Pase, better suppressed the transcriptional levels of genes in the HL group when compared with the HU group (Figure 1(f)). These findings suggested that lobeglitazone efficiently improved hepatic insulin sensitivity in HFD-induced obese mice.

(a)

(b)

(c)

(d)

(e)

(f)

Figure 1: Lobeglitazone treatment improves systemic insulin resistance in high fat diet- (HFD-) fed mice. (a) The glucose tolerance test. Glucose (1 g/kg body weight) was intraperitoneally (i.p.) injected in overnight-fasted mice. (b) The insulin tolerance test. Blood glucose levels were measured at the indicated time points before and after i.p. injection of human regular insulin (0.75 U/kg) in mice fasted for 4 hours. (c) The fasting blood glucose level. (d) The fasting blood insulin level. (e) A homeostasis model for assessment of the insulin resistance index (HOMA-IR). (f) The gene expression levels of PEPCK and G6Pase related to gluconeogenesis were determined by qPCR in liver tissues. NU: normal chow diet- (NCD-) fed mice without treatment (NU, white circles and black bar), HU: HFD-fed mice without treatment (white squares and white bar), and HL: HFD-fed mice with lobeglitazone treatment (black triangles and gray bar). Data are expressed as means ± SEM. p < 0.05, p < 0.001, and p < 0.0001, NU versus HU group. #p < 0.05, ##p < 0.001, and ###p < 0.0001, HU versus. HL group.

3.2. Lobeglitazone Treatment Prevents Hepatic Steatosis in HFD-Induced Obese Mice

Mice liver in the HU group were larger in size and have a lighter color, compared to the relative healthy red color of the mice liver in the HL group (Figure 2(a)). The weights of the livers in the HU group were drastically increased compared with those in the NU group (Figure 2(b)). The weights of the livers in the HL group were also significantly reduced compared to those in the HU group and the HL group exhibited markedly reduced hepatic accumulation of lipids, as assessed by H&E and Oil Red O staining (Figures 2(c) and 2(d)). These results suggested that lobeglitazone mitigated the hepatic steatosis induced by HFD.

(a)

(b)

(c)

(d)

Figure 2: Lobeglitazone treatment ameliorates hepatic steatosis in HFD-fed mice. (a) Representative images of livers of NCD-fed mice without treatment (NU), HFD-fed mice without treatment (HU), and HFD-fed mice with lobeglitazone treatment (HL) after 12 weeks of a HFD. (b) Weight of the livers (g/100 g body weight) of NU (black bar), HU (white bar), and HL (black gray bar). (c) Representative images of hematoxylin and eosin staining and Oil Red O staining of liver sections of HFD-fed mice without treatment (HU) and HFD-fed mice with lobeglitazone treatment (HL). (d) Digital image analysis (DIA) quantification of Oil Red O stained sections. a.u., arbitrary units. Data are expressed as means ± SEM. p < 0.05, p < 0.001, and p < 0.0001, NU versus. HU group. #p < 0.05, ##p < 0.001, and ###p < 0.0001, HU versus. HL group.

3.3. Lobeglitazone Treatment Reduces the Serum Lipid Levels in HFD-Induced Obese Mice

To identify whether lobeglitazone improved the serum lipid profile during histological mitigation of hepatic steatosis, we measured the serum levels of triglycerides (TGs) and cholesterol. Although there was no significant change in the levels of low density lipoprotein cholesterol (LDL-C) (Figure 3(c)), total and high density lipoprotein cholesterol (HDL-C) and TG levels were lower in the HL group than in the HU group (Figures 3(a), 3(b), and 3(d)). To confirm whether the HFD caused the steatohepatitis that was improved by lobeglitazone, we measured the serum levels of alanine aminotransferase (GPT/ALT) and aspartate aminotransferase (GOP/AST), which are hepatic injury markers. The ALT level, but not the AST level, was significantly higher in the HU group than in the NU group (Figures 3(e) and 3(f)), suggesting that the HFD resulted in hepatitis with hepatic lipid accumulation. However, ALT was not significantly lower in the HL group versus the HU group, although ALT was reduced in the HL group (Figures 3(e) and 3(f)) suggesting that lobeglitazone treatment for 4 weeks could not completely recover the hepatic injury caused by the HFD. Taken together, these results showed that lobeglitazone restored the serum lipid levels altered by a HFD.

(a)

(b)

(c)

(d)

(e)

(f)

Figure 3: Lobeglitazone treatment reduces serum cholesterol and triglyceride (TG) levels in HFD-fed mice. Serum concentrations of lipid were measured after 12 weeks of a HFD or NCD. (a) Serum total cholesterol level. (b) Serum high density lipoprotein (HDL) cholesterol level. (c) Serum low density lipoprotein (LDL) cholesterol level. (d) Serum TG level. (e) Alanine aminotransferase (ALT) level. (f) Aspartate aminotransferase (ALP) level. NU: normal chow diet- (NCD-) fed mice without treatment (NU, black bar), HU: HFD-fed mice without treatment (white bar), and HL: HFD-fed mice with lobeglitazone treatment (gray bar). Data are expressed as means ± SEM. p < 0.05, p < 0.001, and p < 0.0001, NU versus. HU group. #p < 0.05, ##p < 0.001, and ###p < 0.0001, HL versus. HU group.

3.4. Lobeglitazone Regulates Hepatic Lipid Metabolism in HFD-Fed Mice

Because lobeglitazone ameliorated lipid accumulation in the liver and restored the serum lipid profile, we evaluated the levels of hepatic protein and gene expression associated with lipid metabolism. Using western blotting, the HL group decreased the protein levels of Srebp1, Srebp2, and ABCA for hepatic lipogenesis and increased the protein levels of PPARα, which mainly included fatty acid β-oxidation and various lipid metabolisms of liver, compared with the HU group (Figure 4(a)). Transcriptional levels of key genes for de novo lipogenesis, such as acetyl-CoA carboxylase 1 (Acc1), Srebp1, Srebp2, and stearoyl-CoA desaturase 1 (Scd1), were significantly decreased in the HL group compared to the HU group (Figure 4(b)). Transcriptional levels of genes for cholesterol biosynthesis, such as HMG-CoA reductase (Hmgcr), squalene epoxidase (Sqle), mevalonate (diphospho) decarboxylase (Mvd), and lanosterol synthase (Lss), were remarkably decreased in the HL group compared to the HU group (Figure 4(c)). The expression levels of genes for lipid droplet development, such as mannosyl (alpha-1,3-)-glycoprotein beta-1,2-N-acetylglucosaminyltransferase (Mgat) 1, Mgat 2, and diacylglycerol-o-acyltransferase 2 (Dgat 2), were also decreased in the HL group compared to the HU group (Figure 4(d)). However, transcriptional levels of acyl-CoA oxidase 1 (Acox1), known as a key gene for fatty acid β-oxidation, was increased in the HL group compared to the HU group (Figure 4(e)). These results showed that the beneficial effects of lobeglitazone on hepatic steatosis were associated with a decrease in hepatic lipid synthesis and an increase in fatty acid β-oxidation.

(a)

(b)

(c)

(d)

(e)

(f)

Figure 4: Lobeglitazone regulates hepatic lipid metabolism in HFD-fed mice. (a) Protein expression of lipid metabolism-related genes in liver tissues. ß-actin was included as a loading control. (b) Expression levels of de novo lipogenesis-related genes in liver tissues. (c) Expression levels of cholesterol biosynthesis-related genes in liver tissues. (d) Expression levels of lipid droplet development-related genes in liver tissues. (e) Expression levels of fatty acid β-oxidation related genes in liver tissues. (f) Protein expression of pPPARγ (S273) and PPARγ in liver tissues. ß-ACTIN was included as a loading control. NU: normal chow diet- (NCD-) fed mice without treatment (NU, black bar), HU: HFD-fed mice without treatment (white bar), and HL: HFD-fed mice with lobeglitazone treatment (gray bar). Data are expressed as means ± SEM. p < 0.05, p < 0.001, and p < 0.0001, NU versus. HU group. #p < 0.05, ##p < 0.001, and ###p < 0.0001, HU versus. HL group.

Recent studies suggested that TZD plays a role in posttranslational modification, as well as agonism, of PPARγ [15]. We therefore evaluated the protein levels of PPARγ and PPARγ phosphorylated at S273 (pPPARγ (S273)) in adipose and liver tissue using western blotting. Although the absolute protein level of PPARγ and pPPARγ (S273) could not compare the liver tissue with adipose tissue, the ratio of pPPARγ (S273) to PPARγ in the NU group was very high in liver than in adipose tissue (Figure 4(f) and Supplementary Figure 1). The protein level of PPARγ in liver and adipose tissue were very high in the HU and HL group than in the NU group and did not show the difference between the HU and HL group (Figure 4(f) and Supplementary Figure 1). However, the protein level of pPPARγ (S273) in liver and adipose tissue is significantly lower in the HL group than in the HU group (Figure 4(f) and Supplementary Figure 1). These results showed that lobeglitazone played a role in the posttranslational modification of PPARγ not only in adipose tissue, but also in liver.

4. Discussion

Hepatic steatosis, the first stage of NAFLD, starts with an accumulation of TG in the cytoplasm of hepatocytes and may then progress to nonalcoholic steatohepatitis (NASH), fibrosis, and hepatocellular carcinoma [16, 17]. Although the pathogenic pathways associated with inflammation, apoptosis, and fibrosis have been studied by researchers as possible therapeutic targets [18], most drugs were not used for the treatment of NASH, either because of insufficient potency to inhibit the progression of NASH, or because of alternative pathways that retained the NASH phenotype. Current attempts to treat NAFLD have emphasized correcting insulin resistance, which is an almost constant finding in NAFLD [19]. PPARγ activator TZD, which acts as a potent insulin sensitizer used for treatment of T2DM, has attempted as a treatment for NAFLD. Many studies showed that rosiglitazone and pioglitazone significantly improved hepatic steatosis [20, 21], and this effect of these drugs is largely explained by the secondary effect of improving the insulin sensitivity of adipose tissue, where PPARγ level is mainly high [7, 8]. Recent studies have suggested that the structural differences among TZDs might not only result in increased PPARγ expression, but also result in ligand-dependent posttranslational modifications of PPARγ [15, 22]. Lobeglitazone contains a common TZD moiety, but with different side chains compared with rosiglitazone and pioglitazone [9, 13]. Therefore, we hypothesized that the novel TZD, lobeglitazone, could be used as a potent drug for the treatment of NAFLD in an HFD-induced obese mouse model.

Recently, T2DM patients treated with lobeglitazone not only improved their insulin sensitivity and glucose intolerance, but also showed an improvement in NASH [12]. Consistent with previous studies [9, 11], we confirmed that the HL group had decreased fasting blood glucose levels and enhanced insulin sensitivity when compared with the HU group (Figure 1). In addition, mice in the HL group had effectively increased weight of adipose tissue compared with the HU group (data not shown). It could indicate that lobeglitazone has worked appropriately as a PPARγ activator which promotes the proliferation and differentiation of adipocytes [23]. Therefore, the effects of lobeglitazone in adipose tissue would play a role in improving the insulin sensitivity in the HL group. Mice in the HL group had decreased liver weight but did not have significantly lower levels of liver enzymes. Obesity involves the recruitment of macrophages according to lipid accumulation in the liver [24] and increases in levels of hepatic enzymes such as GPT/ALT and GOP/AST during the progression of an inflammatory reaction (i.e., NASH). In this study, although short-term lobeglitazone treatment for 4 weeks failed to reverse the inflammatory response in the HL group, the HL group not only showed improved lipid accumulation in the liver (Figure 2), but also significantly decreased total cholesterol and TG levels (Figure 3). Because the primary target site of lobeglitazone is the liver [13], lobeglitazone may first alter lipid metabolism rather than inflammatory pathway in the liver.

NAFLD can be induced by altering hepatic lipid metabolism, through enhancing hepatic lipid accumulation and attenuating the increase in serum lipid levels [25]. Because PPARα is mainly expressed in liver tissue and play important roles in lipid uptake and storage of liver tissue, the regulation of hepatic PPARα is necessary for the treatment of NAFLD. PPARα plays an important role in lipid catabolism through induction of mitochondrial fatty acid β-oxidation in liver tissue [26]. A recent study reported that hepatic PPARα played a central role in the clearance of free fatty acids released from adipocytes, which are the major source of lipids in NAFLD [27]. In this study, PPARα levels in the HL group increased in the liver with transcriptional induction of genes involving fatty acid β-oxidation, as well as transcriptional inhibition of genes involved in lipid synthesis, cholesterol biosynthesis, and lipid droplet development (Figure 4). Therefore, the effects of lobeglitazone on NAFLD could be due more to the effect on PPARα than on rosiglitazone and pioglitazone.

PPARγ was generally lower levels in liver tissue in adipose tissue and could have less important roles than PPARα for lipid metabolism of liver. However, in this study, HFD in mice induced the protein levels of PPARγ and phosphorylation of PPARγ at S273 (pPPARγ (S273)), not only in adipose tissue but also in liver tissue (Figure 4(f) and Supplementary Figure 1). Treatment of lobeglitazone lowered the pPPARγ (S273) in adipose and liver tissue (Figure 4 and Supplementary Figure 1). Cdk5-mediated phosphorylation of PPARγ at S273 induced by HFD has been linked to insulin resistance [15]. One study also reported that inhibition of pPPARγ (S273) ameliorated hepatic steatosis [28]. Therefore, the improvement of hepatic steatosis in the HL group might have been associated with a decrease in this phosphorylation although we did not confirm whether pPPARγ (S273) in the liver altered gene expression.

In conclusion, we showed that lobeglitazone conferred potentially beneficial effects on insulin sensitivity and hepatic steatosis through improvement of lipid metabolism via altering the expression of target genes involved in these pathways. The changes in gene expression may be due to the induction of PPARα and inhibition of pPPARγ phosphorylation at S273. This study therefore suggests an important role for lobeglitazone in modulating hepatic steatosis, as well as suggesting a novel therapy for the treatment of NAFLD.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Authors’ Contributions

Sorim Choung and Kyong Hye Joung contributed equally to this work.

Acknowledgments

This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korean Government (NRF-2016R1D1A1A09916900) (to Bon Jeong Ku), financed with a grant from Chong Kun Dang Pharmaceuticals, Republic of Korea (2015-2083-01) (to Bon Jeong Ku), and funded by a grant from the Korean Diabetes Association (to Kyong Hye Joung, 2013).

Supplementary Materials

Supplementary Figure 1: protein expression of pPPARγ (S273) and PPARγ in adipose tissues. ß-ACTIN was included as a loading control. (Supplementary Materials)

References

A. Sonsuz, M. Basaranoglu, and G. Ozbay, “Relationship between aminotransferase levels and histopathological findings in patients with nonalcoholic steatohepatitis [8],” American Journal of Gastroenterology, vol. 95, no. 5, pp. 1370-1371, 2000.

Y.-H. Lee, J. H. Kim, S. R. Kim et al., “Lobeglitazone, a novel thiazolidinedione, improves non-alcoholic fatty liver disease in type 2 diabetes: Its efficacy and predictive factors related to responsiveness,” Journal of Korean Medical Science, vol. 32, no. 1, pp. 60–69, 2017.

G. C. Farrell and C. Z. Larter, “Nonalcoholic fatty liver disease: from steatosis to cirrhosis,” Hepatology, vol. 43, no. 2, pp. S99–S112, 2006.

J. D. Browning and J. D. Horton, “Molecular mediators of hepatic steatosis and liver injury,” The Journal of Clinical Investigation, vol. 114, no. 2, pp. 147–152, 2004.

A. Szanto and L. Nagy, “The many faces of PPARγ: anti-inflammatory by any means?” Immunobiology, vol. 213, no. 9-10, pp. 789–803, 2008.

P. Tontonoz and B. M. Spiegelman, “Fat and beyond: the diverse biology of PPARγ,” Annual Review of Biochemistry, vol. 77, pp. 289–312, 2008.

J. G. Yu, S. Javorschi, A. L. Hevener et al., “The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects,” Diabetes, vol. 51, no. 10, pp. 2968–2974, 2002.

A. Xu, Y. Wang, H. Keshaw, L. Y. Xu, K. S. L. Lam, and G. J. S. Cooper, “The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice,” The Journal of Clinical Investigation, vol. 112, no. 1, pp. 91–100, 2003.

J. W. Kim, J.-R. Kim, S. Yi et al., “Tolerability and Pharmacokinetics of Lobeglitazone (CKD-501), a Peroxisome Proliferator-Activated Receptor-γ Agonist: A Single- and Multiple-Dose, Double-Blind, Randomized Control Study in Healthy Male Korean Subjects,” Clinical Therapeutics, vol. 33, no. 11, pp. 1819–1830, 2011.

K. Bae, J. B. Seo, Y. Jung et al., “Lobeglitazone, a Novel Peroxisome Proliferator-Activated Receptor γ Agonist, Attenuates Renal Fibrosis Caused by Unilateral Ureteral Obstruction in Mice,” Endocrinology and Metabolism Clinics of North America, vol. 32, no. 1, pp. 115–123, 2017.

G. Kim, Y. Lee, M. R. Yun et al., “Effects of lobeglitazone, a novel thiazolidinedione, on adipose tissue remodeling and brown and beige adipose tissue development in db/db mice,” International Journal of Obesity, vol. 42, no. 3, pp. 542–551, 2017.

S. G. Kim, D. M. Kim, J.-T. Woo et al., “Efficacy and safety of lobeglitazone monotherapy in patients with type 2 diabetes mellitus over 24-weeks: a multicenter, randomized, double-blind, parallel-group, placebo controlled trial,” PLoS ONE, vol. 9, no. 4, Article ID e92843, 2014.

J.-H. Lee, C.-K. Noh, C.-S. Yim et al., “Kinetics of the Absorption, Distribution, Metabolism, and Excretion of Lobeglitazone, a Novel Activator of Peroxisome Proliferator-Activated Receptor Gamma in Rats,” Journal of Pharmaceutical Sciences, vol. 104, no. 9, pp. 3049–3059, 2015.

A. Mehlem, C. E. Hagberg, L. Muhl, U. Eriksson, and A. Falkevall, “Imaging of neutral lipids by oil red O for analyzing the metabolic status in health and disease,” Nature Protocols, vol. 8, no. 6, pp. 1149–1154, 2013.

J. H. Choi, A. S. Banks, J. L. Estall et al., “Anti-diabetic drugs inhibit obesity-linked phosphorylation of PPARγ 3 by Cdk5,” Nature, vol. 466, no. 7305, pp. 451–456, 2010.

J. C. Cohen, J. D. Horton, and H. H. Hobbs, “Human fatty liver disease: old questions and new insights,” Science, vol. 332, no. 6037, pp. 1519–1523, 2011.

L. Hebbard and J. George, “Animal models of nonalcoholic fatty liver disease,” Nature Reviews Gastroenterology & Hepatology, vol. 8, no. 1, pp. 35–44, 2011.

V. Ratziu, Z. Goodman, and A. Sanyal, “Current efforts and trends in the treatment of NASH,” Journal of Hepatology, vol. 62, no. 1, pp. S65–S75, 2015.

A. Wree, L. Broderick, A. Canbay, H. M. Hoffman, and A. E. Feldstein, “From NAFLD to NASH to cirrhosis-new insights into disease mechanisms,” Nature Reviews Gastroenterology & Hepatology, vol. 10, no. 11, pp. 627–636, 2013.

V. Ratziu, P. Giral, S. Jacqueminet et al., “Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial,” Gastroenterology, vol. 135, no. 1, pp. 100–110, 2008.

A. J. Sanyal, N. Chalasani, K. V. Kowdley et al., “Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis,” The New England Journal of Medicine, vol. 362, no. 18, pp. 1675–1685, 2010.

J. H. Choi, A. S. Banks, T. M. Kamenecka et al., “Antidiabetic actions of a non-agonist PPARγ ligand blocking Cdk5-mediated phosphorylation,” Nature, vol. 477, no. 7365, pp. 477–481, 2011.

Z. Xu, G. Wang, Y. Zhu et al., “PPAR-γ agonist ameliorates liver pathology accompanied by increasing regulatory B and T cells in high-fat-diet mice,” Obesity, vol. 25, no. 3, pp. 581–590, 2017.

S. E. Kahn, R. L. Hull, and K. M. Utzschneider, “Mechanisms linking obesity to insulin resistance and type 2 diabetes,” Nature, vol. 444, no. 7121, pp. 840–846, 2006.

B. W. Smith and L. A. Adams, “Nonalcoholic fatty liver disease and diabetes mellitus: pathogenesis and treatment,” Nature Reviews Endocrinology, vol. 7, no. 8, pp. 456–465, 2011.

A. Minnich, N. Tian, L. Byan, and G. Bilder, “A potent PPARα agonist stimulates mitochondrial fatty acid β-oxidation in liver and skeletal muscle,” American Journal of Physiology-Endocrinology and Metabolism, vol. 280, no. 2, pp. E270–E279, 2001.

A. Montagner, A. Polizzi, E. Fouché et al., “Liver PPARa is crucial for whole-body fatty acid homeostasis and is protective against NAFLD,” Gut, vol. 65, pp. 1202–1214, 2016.

S. S. Choi, E.-S. Kim, and J.-E. Jung, “PPARgamma antagonist gleevec improves insulin sensitivity and promotes the browning of white adipose tissue,” Diabetes, vol. 65, no. 4, pp. 829–839, 2016.